DXCM News and Press, DexCom Inc. From 07/29/22

Shares of DexCom (NASDAQ: DXCM) were falling 5.2% lower as of 11:15 a.m. ET on Friday after sinking as much as 10.9% earlier in the day. The decline came after the diabetes-care technology company announced its second-quarter financial results after the market close on Thursday. ...

Avaya Holdings ( AVYA ) -23% on disappointing Q3 prelim results. Roku ( ROKU ) -21% as analysts rush to downgrade following Q2 miss, weak guidance. DexCom ( DXCM ) -13% on Q2 results. Intel ( INTC ) -12% on Q2 results. Cr...

Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q2 2022 Earnings Call Jul 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: DexCom (DXCM) Q2 2022 Earnings Call Transcript

DexCom, Inc. (DXCM) Q2 2022 Earnings Conference Call July 28, 2022, 4:30 PM ET Company Participants Sean Christensen - Investor Relations Kevin Sayer - Chairman, President and CEO Jereme Sylvain - Chief Financial Officer Conference Call Participants R...

The following slide deck was published by DexCom, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: DexCom, Inc. 2022 Q2 - Results - Earnings Call Presentation

DexCom ( NASDAQ: DXCM ) stock fell 7.1% to $80.85 after hours Thursday, as the diabetes medical device maker reported Q2 earnings that missed estimates. DXCM posted Q2 non-GAAP EPS of $0.17 which missed expectations by $0.02. Its Q2 revenue of $696.2M also missed b...

DexCom press release ( NASDAQ: DXCM ): Q2 Non-GAAP EPS of $0.17 misses by $0.02 . Revenue of $696.2M (+17.0% Y/Y) misses by $13.13M . Shares -7% . Non-GAAP Gross Profit Margin of approximately 65% Non-GAAP Operating Margin of approximately 16% ...

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022. Second Quarter 2022 Financial Highlights: Revenue grew 17% versus the same quarter of the prior year to $696.2 million on a reported basis and 16% on an orga...

DexCom ( NASDAQ: DXCM ) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close. The consensus EPS Estimate is $0.19 (-75.0% Y/Y) and the consensus Revenue Estimate is $709.33M (+19.2% Y/Y). Over the last 2 years, DXCM has beaten EPS e...

Don't let DexCom 's (NASDAQ: DXCM) drop of 38% this year fool you: This business is teeming with growth, and it's still fully capable of being a great long-term investment, especially starting this week. The medical device manufacturer will report its second-quarter earnings after t...